Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata

    August 2023 in “ JAMA Dermatology ”
    Justin Ko, Tiffany T. Mayo, Wilma F. Bergfeld, Yves Dutronc, Guanglei Yu, Susan Ball, Najwa Somani, Brittany G. Craiglow
    Image of study
    TLDR Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
    The document presents a pooled analysis of two phase 3 randomized clinical trials (BRAVE-AA1 and BRAVE-AA2) involving 1200 adult patients with severe alopecia areata (AA). The study found that 25% of patients who did not respond to a 2 mg dose of baricitinib (a Janus kinase 1/2 inhibitor) showed significant hair regrowth when the dose was increased to 4 mg. Specifically, these patients achieved at least 80% scalp coverage by week 76. Additionally, response rates for clinician-reported outcome scores for eyebrows and eyelashes also increased. The study concludes that patients with severe AA not achieving successful regrowth of scalp hair with baricitinib, 2 mg, may benefit from uptitration to baricitinib, 4 mg.
    Discuss this study in the Community →

    Research cited in this study

    7 / 7 results

    Related Community Posts Join

    6 / 11 results

      community What else is good. Besides the big 3.

      in Chat  34 upvotes 2 months ago
      Key treatments for hair preservation include minoxidil, finasteride/dutasteride, and microneedling, with additional options like specific shampoos, oils, biotin, zinc, tretinoin, clascoterone, and low-level laser therapy. Maintaining a healthy lifestyle, reducing stress, and addressing nutrient deficiencies can also support hair health.

      community I am a dermatologist with a clinical interest in alopecia. AMA

      in Will treatment work for me? 2 years ago
      In this conversation, 4990 discussed various treatments for hair loss, including oral minoxidil, PRP, transplan, Jak inhibitors, Dutasteride, Finasteride, Olumiant, Ketoconazole, RU58841, microneedling, baricitinib, and CCCA. They recommended scalp biopsies in unclear cases of DUPA, twice weekly to twice daily shampooing for topical minoxidil users, and two sessions spaced one month apart with follow up at month three to determine the effectiveness of PRP treatment.

      community Olumiant active ingredient Baricitinib

      in Research/Science  1 upvotes 2 years ago
      The conversation is about someone inquiring if anyone has tried Olumiant or its active ingredient, Baricitinib, for hair loss, mentioning the cost and that they have ordered Baricitinib.

    Related Research

    1 / 1 results